Revolutionizing Industries: Unleashing the Power of Global API Intermediates for Enhanced Connectivity and Innovation

The global API intermediates market refers to the expansive industry involved in producing and supplying intermediary compounds used in synthesizing active pharmaceutical ingredients (APIs). API intermediates play a vital role in combating diseases such as Alzheimer's. With 5.8 million cases in 2020, projected to reach 14 million, the urgency to develop effective pharmaceutical interventions underscores the importance of the global API intermediates market in addressing the growing prevalence of Alzheimer's disease, a significant public health challenge.

Access Full Report @ https://www.databridgemarketresearch.com/de/reports/global-api-intermediates-market

Data Bridge Market Research analyses that the Global API Intermediates Market, which was USD 2.34 billion in 2022, is expected to reach USD 5.67 billion by 2030 and undergo a CAGR of 7.10% during the forecast period of 2023-2030. Continuous progress in pharmaceutical manufacturing technologies enhances the efficiency and cost-effectiveness of API intermediates. These advancements not only streamline production processes but also contribute to the overall growth of the global API intermediates market by meeting industry demands for more sophisticated and economically viable solutions.

Key Findings of the Study

Rise in the geriatric population base globally is expected to drive the market's growth rate

The rising geriatric population, susceptible to age-related ailments, is driving market growth. With a higher likelihood of health issues among the elderly, the market benefits from increased demand for solutions. The surge in chronic diseases such as cancer, diabetes, and cardiovascular and respiratory conditions poses a significant healthcare burden. Addressing these prevalent disorders becomes crucial for market players, physicians, and patients, making the aging population a pivotal determinant for market expansion.

Report Scope and Market Segmentation

Segment Analysis:

The global API intermediates market is segmented on the basis of the type, product, therapeutic type, customers, end users, and distribution channel. 

• On the basis of type, global API intermediates market is segmented into veterinary drug intermediates and pharmaceutical / bulk drug intermediates. The pharmaceutical / bulk drug intermediates segment is expected to dominate the market with a 70.90% market share due to rising demand for APIs for producing finished goods and the rising prevalence of various disease

The pharmaceutical / bulk drug intermediates is expected to dominate the global API intermediates market during the forecast period of 2023 to 2030

 The pharmaceutical / bulk drug intermediates segment is expected to dominate the market with a 70.90% market share due to rising demand for APIs for producing finished goods and the rising prevalence of various diseases that require continued production of drugs.

• On the basis of product, the global API intermediates market is segmented into bromo compound, O-benzyl salbutamol, hemisulfate, oxirane, bisoprolol base, chiral PCBHP, pheniramine base, chlorpheniramine base, brompheniramine base, mepyramine/pyrilamine base, 6-amino-1,3-dimethyl uracil, theofylline, acefylline, xanthine, nitriles, and others. The Nitriles segment is expected to dominate the market with an 8.92% market share due to the high cost of the products and continued research and development for the innovative APIs
• On the basis of therapeutic type, the global API intermediates market is segmented into autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, urology, and others. Cardiovascular diseases segment is expected to dominate the market with 18.40% market share because cardiovascular is the leading cause of death globally
• On the basis of customers, the global API intermediates market is segmented into direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/pvt institutions. The direct users/pharma companies segment is expected to dominate the market with 56.73% market share because APIs manufacturers is the intermediates' primary and direct user. Rising Contract manufacturing also boosts the market  
• On the basis of end users, the global API intermediates market is segmented into API manufacturer, and finished product manufacturer. API manufacturer segment is expected to dominate the market with 62.71% market share because intermediates are the primary chemical substrate of the APIs, which can be further converted into APIs. The API manufacturer widely uses the intermediates to reduce the cost of manufacturing
• On the basis of distribution channel, the global API intermediates market is segmented into direct tender, retail sale, and others. The direct tender segment will emerge as the dominating segment with 66.32% market share. This is because of the cost of healthcare; healthcare service providers are focusing on better services for customers and reducing the overall cost

Direct tender dominates the distribution channel segment of the API intermediates market during the forecast period of 2023 to 2030

The direct tender segment will emerge as the dominating segment with a 66.32% market share. This is because of the cost of healthcare; healthcare service providers are focusing on better services for customers and reducing the overall cost.

Major Players

Data Bridge Market Research recognizes the following companies as the major global API intermediates market players in global API intermediates market are HIKAL Ltd. (India), Cambrex Corporation (U.S.), Ganesh-Group, AlzChem Group AG (India), Vasudha Pharma (India), Anyang General Chemical Co.,Ltd. (China), Sarex (India), Sandoo Pharmaceuticals and Chemicals Co., Ltd (India).

Market Developments

• In January 2023, Novartis finalized the sale of its active pharmaceutical ingredient (API) manufacturing facility in Ringaskiddy, Ireland, to Sterling Pharma Solutions. Despite the ownership transfer, Novartis retains the responsibility for manufacturing multiple APIs crucial for cardiovascular, immunology, and oncology medicines at the Ringaskiddy facility, ensuring the continued production of vital pharmaceutical components under the terms of the agreement
• In January 2021, Vertellus were acquired by the company, Pritzker Private Capital who partners with middle-market companies established in North America and builds up the long-term relationship with that company. As Vertellus is considered a leading company or provider of specialty chemicals in different sectors such as healthcare, food & agriculture, personal care, transportation, and coatings, PPC has partnered with the company. This helped the company, Vertellus, increase its market growth, which will drive their company's revenues
• In November 2020, Cambrex Corporation announced that the company will expand their API manufacturing capacity to meet the increasing consumer demand. The company has invested USD 50 million to enhance its manufacturing capacity. The increase in API manufacturing will directly increase the production and requirement of intermediates, which means that the company has to increase the manufacturing of both API and their intermediates. This expansion helped the company enhance its production in both the fields that are APIs and their intermediaries, which will increase the company revenues
• In August 2020, Dishman Carbogen Amcis Ltd announced that the company would expand the API manufacturing capacity of Switzerland-based CARBOGEN AMCIS to meet consumer demand. The company has invested USD 110.46 million to enhance its manufacturing capacity. The increase in API manufacturing will directly increase the production and requirement of intermediates, which means that the company has to increase the manufacturing of both API and their intermediates. This expansion helped the company enhance its production in both the fields of APIs and their intermediaries, which will increase the company revenue

Regional Analysis

Geographically, the countries covered in the global API intermediates market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa.

As per Data Bridge Market Research analysis:

North America is the dominant region in the global API intermediates market during the forecast period 2023-2030

North America dominates the global API intermediates market, poised for substantial growth from 2023 to 2030. Fueled by escalating healthcare expenditure and a robust healthcare infrastructure, particularly in the pharmaceutical and bulk drug intermediates segment, the region is positioned for the highest growth rate. This reflects a strong commitment to advancing healthcare capabilities and meeting the demands of the evolving pharmaceutical industry.

Asia-Pacific is estimated to be the fastest-growing region in the global API intermediates market for the forecast period 2023-2030

Asia Pacific is expected to dominate the global API intermediates market, with the pharmaceutical/bulk drug intermediates segment leading the region's growth. The prevalence of this dominance is attributed to the increased availability of API intermediates at lower costs, positioning the region as a key player in driving market expansion. The cost efficiency contributes significantly to the pharmaceutical sector's robust performance in the Asia Pacific region.

For more detailed information about the global API intermediates market report, click here – https://www.databridgemarketresearch.com/de/reports/global-api-intermediates-market